+关注
你好啊天道酬勤
暂无个人介绍
IP属地：河北
1
关注
0
粉丝
0
主题
0
勋章
主贴
热门
你好啊天道酬勤
08-25
？她1484*98-133
$恒生指数主连 2604(HSImain)$
[冷漠]
歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"4113047598343120","uuid":"4113047598343120","gmtCreate":1649944526282,"gmtModify":1649944526282,"name":"你好啊天道酬勤","pinyin":"nhatdcqnihaoatiandaochouqin","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":1,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":2,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.05.26","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"河北","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":600457860937072,"gmtCreate":1787622032230,"gmtModify":1787622550846,"author":{"id":"4113047598343120","authorId":"4113047598343120","name":"你好啊天道酬勤","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4113047598343120","authorIdStr":"4113047598343120"},"themes":[],"title":"","htmlText":"？她1484*98-133<a href=\"https://laohu8.com/FUT/HSImain\">$恒生指数主连 2604(HSImain)$ </a> [冷漠] ","listText":"？她1484*98-133<a href=\"https://laohu8.com/FUT/HSImain\">$恒生指数主连 2604(HSImain)$ </a> [冷漠] ","text":"？她1484*98-133$恒生指数主连 2604(HSImain)$ [冷漠]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600457860937072","repostId":"2661600092","repostType":2,"repost":{"id":"2661600092","kind":"news","pubTimestamp":1787314847,"share":"https://www.laohunote.com/m/news/2661600092?lang=zh_CN&edition=full","pubTime":"2026-08-21 20:20","market":"hk","language":"zh","title":"歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661600092","media":"智通财经","summary":"智通财经APP讯，歌礼制药-B 发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线的战略承诺。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01672\">歌礼制药-B</a>(01672)发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。</p><p>本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。</p><p>董事会认为于本报告期本公司权益股东应占亏损增加主要是由于研发开支由截至2025年6月30日止6个月的约人民币1.468亿元大幅增加约 132.7%至本报告期的约人民币3.417亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线(包括小分子及多肽)的战略承诺。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 20:20 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1483596.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。董事会认为于本...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1483596.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01672":"歌礼制药-B","BK1515":"抗疫概念","BK1191":"制药","01477":"欧康维视生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1483596.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2661600092","content_text":"智通财经APP讯，歌礼制药-B(01672)发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。董事会认为于本报告期本公司权益股东应占亏损增加主要是由于研发开支由截至2025年6月30日止6个月的约人民币1.468亿元大幅增加约 132.7%至本报告期的约人民币3.417亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线(包括小分子及多肽)的战略承诺。","news_type":1,"symbols_score_info":{"01477":1.5,"01672":1.5}},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":600457860937072,"gmtCreate":1787622032230,"gmtModify":1787622550846,"author":{"id":"4113047598343120","authorId":"4113047598343120","name":"你好啊天道酬勤","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4113047598343120","authorIdStr":"4113047598343120"},"themes":[],"title":"","htmlText":"？她1484*98-133<a href=\"https://laohu8.com/FUT/HSImain\">$恒生指数主连 2604(HSImain)$ </a> [冷漠] ","listText":"？她1484*98-133<a href=\"https://laohu8.com/FUT/HSImain\">$恒生指数主连 2604(HSImain)$ </a> [冷漠] ","text":"？她1484*98-133$恒生指数主连 2604(HSImain)$ [冷漠]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600457860937072","repostId":"2661600092","repostType":2,"repost":{"id":"2661600092","kind":"news","pubTimestamp":1787314847,"share":"https://www.laohunote.com/m/news/2661600092?lang=zh_CN&edition=full","pubTime":"2026-08-21 20:20","market":"hk","language":"zh","title":"歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661600092","media":"智通财经","summary":"智通财经APP讯，歌礼制药-B 发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线的战略承诺。","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/01672\">歌礼制药-B</a>(01672)发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。</p><p>本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。</p><p>董事会认为于本报告期本公司权益股东应占亏损增加主要是由于研发开支由截至2025年6月30日止6个月的约人民币1.468亿元大幅增加约 132.7%至本报告期的约人民币3.417亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线(包括小分子及多肽)的战略承诺。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药-B(01672)发盈警，预期中期股东应占亏损约3.197亿元 同比增加约263.5%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-21 20:20 北京时间 <a href=http://www.zhitongcaijing.com/content/detail/1483596.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，歌礼制药-B(01672)发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。董事会认为于本...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1483596.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"01672":"歌礼制药-B","BK1515":"抗疫概念","BK1191":"制药","01477":"欧康维视生物-B","BK1161":"生物科技","BK1574":"生物医药B类股"},"source_url":"http://www.zhitongcaijing.com/content/detail/1483596.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2661600092","content_text":"智通财经APP讯，歌礼制药-B(01672)发布公告，本集团预期于截至2026年6月30日止6个月取得本公司权益股东应占亏损约人民币3.197亿元，较2025年同期的亏损约人民币8800万元增加约263.5%。本公司拥有充足的在手现金，可支持本公司运营至2029年。于2026年6月30日，本集团现金及现金等价物、定期存款、可转让存单、结构性存款及理财产品约为人民币23.05亿元。董事会认为于本报告期本公司权益股东应占亏损增加主要是由于研发开支由截至2025年6月30日止6个月的约人民币1.468亿元大幅增加约 132.7%至本报告期的约人民币3.417亿元。研发开支大幅增加主要由于本集团对推进其全面代谢性疾病产品管线(包括小分子及多肽)的战略承诺。","news_type":1,"symbols_score_info":{"01477":1.5,"01672":1.5}},"isVote":1,"tweetType":1,"viewCount":401,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
